Výsledky vyhledávání

Model-Based Once-Daily Darunavir/Ritonavir Dosing Recommendations in Pediatric HIV-1-Infected Patients Aged ≥3 to12 Years

Autor: A, Brochot, T N, Kakuda, T, Van De Casteele, M, Opsomer, F L, Tomaka, A, Vermeulen, P, Vis

Publikováno v: CPT: Pharmacometrics & Systems Pharmacology

An existing population pharmacokinetic model of darunavir in adults was updated using pediatric data from two studies evaluating weight-based, once-daily dosing of darunavir/ritonavir (ARIEL, NCT00919854 and DIONE, NCT00915655). The model was then us

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::35cbcc080de8a8c0f3e25d7d64ef6556
https://pubmed.ncbi.nlm.nih.gov/26312164

Zobrazit plný text záznamu

The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects

Autor: P J, Ruane, C, Brinson, M, Ramgopal, R, Ryan, B, Coate, M, Cho, T N, Kakuda, D, Anderson, Jennifer, Granit

Publikováno v: HIV medicine. 16(5)

Following antiretroviral therapy failure, patients are often treated with a three-drug regimen that includes two nucleoside/tide reverse transcriptase inhibitors [N(t)RTIs]. An alternative two-drug nucleoside-sparing regimen may decrease the pill bur

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::472d38b2fc521b6a06754656b0c75d58
https://pubmed.ncbi.nlm.nih.gov/25585528

Zobrazit plný text záznamu

Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study

Autor: G, Tudor-Williams, P, Cahn, K, Chokephaibulkit, J, Fourie, C, Karatzios, S, Dincq, M, Opsomer, T N, Kakuda, S, Nijs, L, Tambuyzer, F L, Tomaka, Leonard, Weiner

Publikováno v: HIV medicine. 15(9)

PIANO (Paediatric study of Intelence As an NNRTI Option; TMC125-C213; NCT00665847) assessed the safety/tolerability, antiviral activity and pharmacokinetics of etravirine plus an optimized background regimen (OBR) in treatment-experienced, HIV-1-infe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::88fe7e7a6c70f1eedfc877a9baf304ef
https://pubmed.ncbi.nlm.nih.gov/24589294

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial

Autor: T N, Kakuda, R, DeMasi, Y, van Delft, P, Mohammed

Publikováno v: HIV medicine. 14(7)

Etravirine is a substrate and inducer of cytochrome P450 (CYP) 3A and a substrate and inhibitor of CYP2C9 and CYPC2C19. Darunavir/ritonavir is a substrate and inhibitor of CYP3A. Artemether and lumefantrine are primarily metabolized by CYP3A; artemet

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::77f7cbbc1759b6215e31d77b2c9c2e2d
https://pubmed.ncbi.nlm.nih.gov/23441978

Zobrazit plný text záznamu

Safety and pharmacokinetics of etravirine in pregnant HIV-1-infected women

Autor: P, Izurieta, T N, Kakuda, C, Feys, J, Witek

Publikováno v: HIV medicine. 12(4)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::98a96902a24bce38c110cf9927f316d3
https://pubmed.ncbi.nlm.nih.gov/21371239

Zobrazit plný text záznamu

Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: study TMC125-C227*

Autor: K, Ruxrungtham, R J, Pedro, G H, Latiff, F, Conradie, P, Domingo, S, Lupo, W, Pumpradit, J H, Vingerhoets, M, Peeters, I, Peeters, T N, Kakuda, G, De Smedt, B, Woodfall, Alastair, Teague

Publikováno v: HIV Medicine.

Objectives TMC125-C227, an exploratory phase II, randomized, controlled, open-label trial, compared the efficacy and safety of TMC125 (etravirine) with an investigator-selected protease inhibitor (PI) in nonnucleoside reverse transcriptase inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1a101e7d834c291f6de77b3e8d9f279
https://doi.org/10.1111/j.1468-1293.2008.00644.x

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání